Abbott Laboratories (ABT) investor relations material

Executive summary

• Q2 2026 reported sales grew 13.0% to $12.6B, with comparable sales up 4.8%; adjusted diluted EPS was $1.312, exceeding guidance and consensus.

• The Exact Sciences acquisition, completed in March 2026, contributed $1.0B in sales and established a presence in cancer diagnostics.

• Key business units posted strong sales: Medical Devices $5.9B, Diagnostics $3.1B, Nutrition $2.1B, Established Pharmaceuticals $1.5B.

• $2.1B was returned to shareholders in Q2 via dividends and share repurchases; quarterly dividend increased to $0.63 per share.

• Notable milestones include completion of TECTONIC trial enrollment, CE Mark for Libre Duo, and FDA submission for Amulet 360.

Financial highlights

• Q2 2026 net sales: $12.6B (+13.0% reported, +4.8% comparable); GAAP diluted EPS: $0.53; adjusted diluted EPS: $1.312.

• Gross margin for Q2 2026: 52.5%; adjusted gross margin: 58.0% of sales, up 100 bps year-over-year.

• Q2 2026 operating earnings: $1.69B; net earnings: $928M; adjusted net earnings: $2.29B.

• Adjusted R&D: 6.9% of sales; adjusted SG&A: 28.6% of sales.

• Foreign exchange had a favorable 0.8% impact on Q2 sales.

Outlook and guidance

• Full-year 2026 comparable sales growth guidance reaffirmed at 6.5%–7.5%; adjusted EPS guidance raised to $5.45–$5.60.

• Q3 2026 adjusted EPS projected at $1.38–$1.46.

• Growth acceleration in H2 expected from nutrition, electrophysiology, core lab, and cancer diagnostics.

• Integration of Exact Sciences expected to drive further expansion in cancer diagnostics.